Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules

Journal of Clinical Pharmacology

Volumn 45, Issue 5, 2005, Pages 547-554

  Vashi, Vijay ^a   Harris, Stephen ^a   El Tahtawy, Ahmed ^a   Wu, Danlin ^b   Cipriano, Alessandra ^a  

^a PURDUE PHARMA L P   (United States)

^b Purdue Research Center   (United States)

Author keywords

Extended release hydromorphone HCl; Pharmacokinetics

Indexed keywords

HYDROMORPHONE; NALOXONE; NALTREXONE;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG RELEASE; HUMAN; SIDE EFFECT; STEADY STATE;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYDROMORPHONE; MALE;

EID: 17644392128     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005274552     Document Type: Article

References (9)

1. Riesine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:535.
2. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84-96.
3. Weinstein S, Lacouture PG, Grosser AB, et al. Two double blind randomized trials of once-a-day controlled release oral hydromorphone (Palladone XL) compared to immediate release hydromorphone dosed QID. Presented at: American Pain Society 18th annual meeting, October 1999; Ft. Lauderdale, Fla. Abstract 645.
4. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Bethesda, Md: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001.
5. Food and Drug Administration: Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Bethesda, Md: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2003. Revision 1.
6. Durnin C, Hind ID, Ghani SP, Yates DB, Cross M. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in young and elderly subjects. Proc West Pharmacol Soc. 2001;44:79-80.
7. Durin C, Hind ID, Channon E, Yates DB, Cross M. Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR). Proc West Pharmacol Soc. 2001;44:75-76.
8. Durin C, Hind ID, Ghani SP, Yates DB, Cross M. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR). Proc West Pharmacol Soc. 2001;44:73-74.
9. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97:827-836.